Impacts of intravitreal anti-VEGF therapy on retinal anatomy and neurophysiology in diabetic macular edema

被引:5
|
作者
Yozgat, Zubeyir [1 ]
Dogan, Mustafa [1 ]
Sabaner, Mehmet Cem [1 ]
Gobeka, Hamidu Hamisi [2 ]
Yazgan Akpolat, Serpil [3 ]
机构
[1] Afyonkarahisar Hlth Sci Univ, Afyon, Turkey
[2] Ibrahim Cecen Univ Agri, Agri Merkez, Turkey
[3] Malatya Inonu Univ, Malatya, Turkey
关键词
Aflibercept; Diabetic macular edema; Fundus fluorescein angiography; Microperimetry; Multifocal electroretinography; Optical coherence tomography;
D O I
10.1007/s10792-021-01737-w
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate anatomical and neuroretinal functional aspects in patients with diabetic macular edema (DME) after intravitreal anti-vascular endothelial growth factor (VEGF) therapy, in particular aflibercept. Materials and methods This prospective single-centered interventional study was performed at Afyonkarahisar Health Science University Faculty of Medicine, Department of Ophthalmology, where 32 eyes of 32 patients with DME were investigated. All patients received five intravitreal aflibercept injections on a monthly basis and were followed up for >= 6 months. After a comprehensive ophthalmological examination, including the measurements of visual acuity and intraocular pressure, and an antero-posterior segment slit-lamp biomicroscopy before and after full pupil dilation, fundus fluorescein angiography and optical coherence tomography were performed at baseline and during the third and sixth months post-therapy. Microperimetry and multifocal electroretinography were also performed at baseline and during the sixth months. Results Mean visual acuity increased from 0.73 to 0.57 and 0.33 logarithm of the minimum angle of resolution (logMAR) during the third and sixth months, respectively (p < 0.001). Changes in intraocular pressure were not statistically significant (p = 0.472). There was statistically significantly decreased mean central macular thickness from 390.2 mu m to 242.6 and 289.7 mu m during the third and sixth months, respectively (p < 0.001). Significantly improved fixation patterns during the sixth month, along with significantly increased macular sensitivity from 8.2 to 14.2 dB (p < 0.001) and significantly decreased local deficit from - 10.3 to 5.5 dB (p < 0.001) were observed. Further, there was a significantly increased N1 amplitude in the first ring and significantly increased P1 amplitude in all rings (p for each parameter < 0.05). There was also significantly decreased N1 wave implicit time in all rings and significantly decreased P1 wave in the second, third, fourth and fifth rings (p for each parameter < 0.05). Conclusions Patients with DME showed profound improvement in the retinal neurophysiological function, which was also accompanied by anatomical and ultrastructural integrity recovery after intravitreal aflibercept therapy. In the pathogenesis of DME, the influence of neurodegeneration has been increasingly gaining significant attention. Consequently, the need to assess neurophysiological effects of anti-VEGF therapy using a variety of diagnostic measures like electrophysiological studies and multimodal imaging technologies is undeniably growing.
引用
收藏
页码:1783 / 1798
页数:16
相关论文
共 50 条
  • [21] Factors Affecting a Short-Term Response to Anti-VEGF Therapy in Diabetic Macular Edema
    Usui-Ouchi, Ayumi
    Tamaki, Asaka
    Sakanishi, Yoshihito
    Tamaki, Kazunori
    Mashimo, Keitaro
    Sakuma, Toshiro
    Ebihara, Nobuyuki
    LIFE-BASEL, 2021, 11 (02): : 1 - 9
  • [22] The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment
    In Hwan Hong
    Wonseok Choi
    Jae Ryong Han
    Japanese Journal of Ophthalmology, 2020, 64 : 196 - 202
  • [23] Outer retinal tubulation in diabetic macular edema following anti-VEGF treatment
    Ali M Al-Halafi
    Eye and Vision, 2
  • [24] The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment
    Hong, In Hwan
    Choi, Wonseok
    Han, Jae Ryong
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2020, 64 (02) : 196 - 202
  • [26] Intravitreal Anti-VEGF Therapy for Retinal Macroaneurysm
    Zweifel, S. A.
    Toenz, M. S.
    Pfenninger, L.
    Becker, M.
    Michels, S.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2013, 230 (04) : 392 - 395
  • [27] Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice
    del Cura Mar, Prieto
    Carballes, Maria J. C.
    Sastre-Ibanez, Marina
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2023, 71 (08) : 3091 - 3094
  • [28] Evidence for Anti-VEGF Treatment of Diabetic Macular Edema
    Bandello, F.
    Berchicci, L.
    La Spina, C.
    Parodi, M. Battaglia
    Iacono, P.
    OPHTHALMIC RESEARCH, 2012, 48 : 16 - 20
  • [29] Review on Recent Trials Evaluating the Effect of Intravitreal Injections of Anti-VEGF Agents on the Macular Perfusion of Diabetic Patients with Diabetic Macular Edema
    Elnahry, Ayman G.
    Abdel-Kader, Ahmed A.
    Habib, Ahmed E.
    Elnahry, Gehad A.
    Raafat, Karim A.
    Elrakhawy, Khaled
    REVIEWS ON RECENT CLINICAL TRIALS, 2020, 15 (03) : 188 - 198
  • [30] Metformin therapy as a strategy to compensate anti-VEGF resistance in patients with diabetic macular edema
    Uwimana, Alexandre
    Ma, Cong
    Chen, Shengyao
    Ma, Xiang
    MEDICINE, 2022, 101 (42) : E31266